Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head
- 124 Downloads
This study aimed to analyze the clinical factors related to the failure of autologous bone marrow mononuclear cells grafting (BMMCG) following core decompression (CD) in early stage osteonecrosis of the femoral head (ONFH).
In total, 148 patients (192 hips) underwent CD with autologous BMMCG for treatment of non-traumatic ONFH. The patients were classified by their ARCO staging and China-Japan Friendship Hospital (CJFH) typing system. All patients were clinically and radiographically followed up every three months during the first year and every six months in the following years. The clinical evaluation was conducted by pre- and post-operative Harris hip scores (HHS), while serial anteroposterior (AP) and frog lateral radiographs were used for post-operative radiographic evaluation.
There were 56 hips as clinical failure cases, and 50 hips (89.29%) of failure cases developed between three and ten months after operation. Based on CJFH classification system, type L2 showed more failure rate with 60.0% (9 of15). The Cox risk model showed that disease type was an independent risk factor for post-operative clinical failure (P = 0.042). Multivariate analysis of the Cox proportional-hazards model showed that type L1 had a hazard ratio (HR) of 0.286 (95% CI 0.100–0.816), type L3 with HR of 0.245 (95% CI 0.079–0.759), respectively.
Disease type is an important risk factor for autologous BMMCG combined with CD, and the degree of lateral pillar necrosis is a significant reference index for prognosis evaluation in early stage of ONFH.
KeywordsOsteonecrosis of the femoral head Bone marrow Prognosis Treatment Risk factor
This study was supported by the National Natural Science Foundation of China (81672236, 81372013), and Beijing Natural Science Foundation (7182146).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The procedures performed in this study involving human participants were approved by the ethics committee of China-Japan Friendship Hospital. (File 1)
Informed consent was obtained from all individual participants included in the study. (File 2)
- 3.Tomaru Y, Yoshioka T, Sugaya H, Aoto K, Wada H, Akaogi H et al (2017) Hip preserving surgery with concentrated autologous bone marrow aspirate transplantation for the treatment of asymptomatic osteonecrosis of the femoral head: retrospective review of clinical and radiological outcomes at 6 years postoperatively. BMC Musculoskelet Disord 18(1):292. https://doi.org/10.1186/s12891-017-1652-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Wang BL, Sun W, Shi ZC, Zhang NF, Yue DB, Guo WS et al (2010) Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg 130(7):859–865. https://doi.org/10.1007/s00402-009-0939-0 CrossRefPubMedGoogle Scholar
- 9.Sen RK, Tripathy SK, Aggarwal S, Marwaha N, Sharma RR, Khandelwal N (2012) Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty 27(5):679–686. https://doi.org/10.1016/j.arth.2011.08.008 CrossRefPubMedGoogle Scholar
- 10.Beckmann J, Schmidt T, Schaumburger J, Rath B, Luring C, Tingart M et al (2013) Infusion, core decompression, or infusion following core decompression in the treatment of bone edema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol Int 33(6):1561–1565. https://doi.org/10.1007/s00296-012-2597-8 CrossRefPubMedGoogle Scholar
- 13.Piuzzi NS, Chahla J, Schrock JB, LaPrade RF, Pascual-Garrido C, Mont MA et al (2017) Evidence for the use of cell-based therapy for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplast 32(5):1698–1708. https://doi.org/10.1016/j.arth.2016.12.049 CrossRefGoogle Scholar
- 14.Sun W, Li ZR, Gao FQ, Shi ZC, Wang BL, Guo WS (2014) Porous bioceramic beta-tricalcium phosphate for treatment of osteonecrosis of the femoral head. Zhongguo Zuzhi Gongcheng Yanjiu 16:2474–2479. https://doi.org/10.3969/j.issn.2095-4344.2014.16.003 CrossRefGoogle Scholar
- 16.Piuzzi NS, Chahla J, Jiandong H, Chughtai M, LaPrade RF, Mont MA et al (2017) Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplast. https://doi.org/10.1016/j.arth.2017.02.075
- 18.Wang BL, Li TJ, Yue DB, Sun W (2014) Proliferation ability of bone marrow mesenchymal stem cells in corticosteroid-induced osteonecrosis of femoral head. Zhongguo Zuzhi Gongcheng Yanjiu 1:7–13. https://doi.org/10.3969/j.issn.2095-4344.2014.01.002 CrossRefGoogle Scholar
- 19.Gangji V, De Maertelaer V, Hauzeur JP (2011) Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone 49(5):1005–1009. https://doi.org/10.1016/j.bone.2011.07.032 CrossRefPubMedGoogle Scholar
- 20.Maus U, Roth A, Tingart M, Rader C, Jager M, Noth U et al (2015) S3 guideline. Part 3: non-traumatic avascular necrosis in adults—surgical treatment of atraumatic avascular femoral head necrosis in adults. Z Orthop Unfall 153(5):498–507. https://doi.org/10.1055/s-0035-1545902 CrossRefPubMedGoogle Scholar